-
2024-513959-33-00
4
2025-05-13
Asthma
-
2024-514281-39-00
5
2025-02-14
Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD
-
2024-515008-38-00
5
2025-02-14
Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Expres
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2023-504923-20-00
5
2024-04-04
Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
-
2023-503412-33-00
5
2024-03-29
Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
-
2023-503376-24-00
5
2024-03-20
Metastatic non-small cell lung cancer (NSCLC)
-
2023-505065-91-00
4
2023-01-30
Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small C
-
2024-514266-39-00
7
2022-11-03
Advanced Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors wit
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-520050-38-00
5
2025-09-18
Extensive stage small cell lung cancer (ES-SCLC). S
-
2024-515740-23-00
5
2025-03-25
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
-
2024-512998-27-00
5
2025-02-21
Non-Small Cell Lung Cancer
-
2023-505989-29-00
5
2024-11-21
Extensive stage small cell lung cancer (ES-SCLC)
-
2024-510908-37-00
5
2024-08-28
KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
-
2023-503231-17-00
5
2024-04-26
Unresectable Pleural Mesothelioma
-
2023-503357-35-00
4
2024-03-20
Non-small Cell Lung Cancer (NSCLC)
-
2023-503827-25-01
5
2024-02-16
Non-Small Cell Lung Cancer (NSCLC)
-
2022-502669-14-00
5
2023-12-18
Small cell lung cancer (SCLC)
-
2023-505054-17-00
6
2023-09-15
metastatic TTF-1 negative lung adenocarcinoma
-
2023-505057-40-00
4
2022-12-02
Lung Cancer, Non-Small Cell
-
2023-509825-38-00
5
2022-12-01
Metastatic Non–Small Cell Lung Cancer
-
2023-507964-38-00
5
2022-09-01
Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutate